Northway Biotech Launches Full-Service Viral Clearance Studies, Delivering Results Faster Than Industry Standards
With six newly established, identical BSL-2 laboratories now operational, biologics CDMO Northway Biotech can conduct VCS programs for up to six clients simultaneously, significantly alleviating current market bottlenecks
VILNIUS, LT / ACCESS Newswire / May 5, 2025 / Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), today announced the expansion of its protein-based and gene therapy service offerings with the addition of Viral Clearance Studies (VCS) capabilities. This strategic growth follows the opening of Northway Biotech's new Gene Therapy Center with dedicated cGMP facilities for virus-related projects.
With six newly established, identical BSL-2 laboratories now operational, Northway Biotech can conduct VCS programs for up to six clients simultaneously, significantly alleviating current market bottlenecks. Additionally, the company has expanded its capabilities to perform GMP-compliant manufacturing and testing under BSL-3 conditions, further strengthening its service offering across gene therapy and broader biologics development.
Viral Clearance Studies are now offered both as part of Northway Biotech's integrated CDMO programs and as a standalone service. This flexibility allows external clients to access VCS expertise independently, without requiring a manufacturing agreement.
Accelerated Delivery Timelines - Over One Month Faster Than Industry
Leveraging expanded infrastructure and integrated analytical capabilities, Northway Biotech is positioned to deliver Viral Clearance Studies substantially faster than the current industry standard. Comprehensive studies, assessing viral removal and inactivation, can now be completed with final regulatory-compliant reporting in under 10 weeks from initiation of project design when two model viruses are employed, and within 12 weeks when four model viruses are used.
"Our expansion into Viral Clearance Studies is a natural extension of our CDMO services, enabling us to manage these critical studies in-house and significantly reduce project timelines for our clients," said Prof. Vladas Algirdas Bumelis, CEO of Northway Biotech. "By investing in state-of-the-art BSL-2 and BSL-3 facilities, expanding technical capabilities, and further strengthening our scientific teams, we are uniquely positioned to deliver high-quality VCS data faster - a key advantage for clients advancing through clinical development and regulatory approval."
For more information on Northway Biotech's Viral Clearance Study processes, service offerings, and delivery timelines, please complete the contact form to connect with the Northway Biotech team.
About Northway Biotech - https://www.northwaybiotech.com
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced and professional team executes projects at every stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's extensive expertise and vertically integrated service offering enables rapid execution of multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development, and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and operates locations in Vilnius, Lithuania; London, United Kingdom; and Waltham, MA, USA.
Media & Business Contact:
Prof. Vladas Algirdas Bumelis
CEO and Chairman of the Board
Northway Biotech
vladas.bumelis@northwaybiotech.com
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
View the original press release on ACCESS Newswire
Northway Biotech
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Black Iron Congratulates the U.S. and Ukraine on Their Minerals Deal and Aims to Help Pave the Way With Its Highly Advanced Ukraine New Mining Project5.5.2025 07:16:00 CEST | Press release
U.S. and Ukraine entered into a landmark agreement to jointly develop Ukraine's vast mineral resources. Black Iron (TSX:BKI) is developing the most advanced project to construction in Ukraine. Black Iron's successful construction and operation will create a development roadmap for investments under the U.S. - Ukraine Minerals Agreement. TORONTO, ON / ACCESS Newswire / May 5, 2025 / Black Iron Inc. ("Black Iron" or the "Company") (TSX:BKI)(OTCPK:BKIRF)(FWB:BIN) congratulates Ukraine and the United States governments on signing a landmark agreement to jointly develop Ukraine's vast mineral resources - a strategic move designed to accelerate post-war reconstruction and reduce global dependency on hostile-state supply chains. With potentially trillions of dollars worth of untapped mineral resources and growing Western support, Ukraine is positioning itself as a future powerhouse in the critical minerals sector. The challenge is that there hasn't been a new large-scale mine constructed in U
BioNxt Solutions Reports Expanded Patent Protection from the Eurasian Patent Organization5.5.2025 03:05:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / May 5, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that its first national level patent filing has been accepted by the Eurasian Patent Organization (EAPO). The EAPO has confirmed the Company‘s core patent claims, namely: novelty, inventive step, and industrial applicability. BioNxt's flagship patent filing, which received a positive international examination report from the European Patent Office, reported September 9, 2024, is a comprehensive patent application for sublingual delivery of anticancer drugs for the treatment of autoimmune neurodegenerative diseases. This patent family provides numerous proprietary product development and commercialization opportunities, including BioNxt's lead product, BNT23001, a sublingual thin-film formulation of Cladribine for the treatment of multiple sclerosis (MS). The EA
Polaris Renewable Energy Announces Q1 2025 Results1.5.2025 07:45:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / May 1, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to report its financial and operating results for the three months ended March 31, 2025. This earnings release should be read in conjunction with the Company's condensed consolidated interim financial statements and management's discussion and analysis, which are available on the Company's website at www.PolarisREI.com and have been posted on SEDAR+ at www.sedarplus.ca. The dollar figures below are denominated in US Dollars unless noted otherwise. 2025 HIGHLIGHTS First quarter consolidated energy production of 216,344 MWh, compared to 213,434 MWh in the first quarter last year. The modest increase is mainly attributable to the production of the Puerto Rican wind farm which was acquired on March 3, 2025 and did not contribute to consolidated energy production during the comparative quarter of 2024. The Company generated $20.3 million in revenue
Polaris Renewable Energy Declares Quarterly Dividend1.5.2025 07:45:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / May 1, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to announce that its board of directors has declared a quarterly dividend of US$0.15 per common share outstanding. This dividend will be paid on May 23rd to shareholders of record at the close of business on May 12th. The dividend is an "eligible dividend" as designated for Canadian federal, provincial, and territorial income tax purposes. The board of directors of Polaris Renewable Energy remains committed to paying a quarterly dividend and will evaluate further dividend increases, as appropriate, going forward. About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America & the Caribbean. We are a high-performing and financially sound contributor to the energy transition. The Company's operations inclu
Sensiba Acquires AssuranceLab to Fuel Innovation in Global Cybersecurity and Risk Assurance30.4.2025 18:00:00 CEST | Press release
SAN RAMON, CA AND SYDNEY, AUSTRALIA / ACCESS Newswire / April 30, 2025 / Sensiba LLP, a Top-75 U.S. accounting and consulting firm, is pleased to announce the acquisition of AssuranceLab Pty. Ltd., a high-growth cybersecurity audit and risk assurance firm headquartered in Australia, with operations across the Americas, APAC, and EMEA. This milestone expands Sensiba's international reach and deepens its security, privacy, and compliance framework capabilities. Together, the combined firm now supports over 2,300 startup and technology-driven enterprise clients worldwide-providing streamlined, high-quality audits across more than 15 compliance standards, including SOC 2, ISO/IEC 27001, HIPAA, CSA STAR, and HITRUST. "We're honored to welcome AssuranceLab to Sensiba. Their reputation in the market is well-earned, driven by innovation, credibility, and a commitment to raising the bar for cybersecurity audits. What makes this such a strong fit is the alignment across our values and client ser
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom